Press

Canadian Patent Grant Strengthens Small Pharma’s International Position

Aug 3 • 2 min read

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that as of July 19, 2022 it has been granted patent no. 3104072 by the Canadian Intellectual Property Office. This Canadian patent protects Composition of Matter of certain deuterated analogues of N, N-dimethyltryptamine, including…

Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with plans to expand across the U.S.

Aug 3 • 13 min read

Braxia Scientific Corp., (CSE: BRAX | OTC: BRAXF | FSE: 4960), a leader in the treatment and research of mental health conditions, is pleased to announce it has acquired 100% of the issued and outstanding stock of KetaMD, Inc. KetaMD is a U.S. based, privately-held, innovative telemedicine company, with a mission to address mental health challenges…

Kaya Holdings to Seek Licenses for First Ever State Legal Psilocybin Manufacturing and Facilitation Service Centers in Oregon

Aug 3 • 4 min read

Kaya Holdings, Inc. (OTCQB: KAYS), the first U.S. publicly traded company to hold and operate cannabis licenses in all “touch the plant” categories, announced today that it has initiated the process to seek the requisite licenses for psilocybin manufacturing and facilitation service centers in Oregon. In November 2020 Oregon became the first state in the…

COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference

Aug 2 • 2 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows: BTIG Biotechnology Conference: host investor meetings on 9 August 2022 Canaccord Annual Growth Conference: presentation at 8:30 am ET on 10 August…

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

Aug 2 • 2 min read

atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and business update on Monday, August 15, 2022. A video interview with atai management will be available at 8:30 a.m. (ET) at https://vimeo.com/atailifesciences. The archived video interview will…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441